This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lung Cancer Alliance National Framework Guides Responsible Screening For Those At Risk


WASHINGTON, Jan. 11, 2013 /PRNewswire-USNewswire/ -- Today, in response to the announcement by the American Cancer Society, Lung Cancer Alliance (LCA) President & CEO Laurie Fenton Ambrose said: "We are pleased that the American Cancer Society has joined Lung Cancer Alliance, other leading professional organizations and medical centers around the country in endorsing CT screening for those at high risk for lung cancer."

"No one disputes the results of the National Lung Screening Trial; screening works," she said, referring to the large randomized controlled trial (NLST) launched by the National Cancer Institute in 2002 and terminated in 2010.

"The issues are how to deploy lung cancer screening responsibly and equitably, and how to determine who else will benefit beyond the NLST population of older, heavy smokers. We are addressing these issues through our National Framework for Excellence in Lung Screening and Continuum of Care," Fenton Ambrose explained.

The National Framework, launched by LCA early last year, outlines the rights of the at-risk public, guiding principles for screening sites and also calls for collection of data on outcomes so that lung cancer screening can be continuously improved through a rapid learning process.

"This is important because we have already seen improvements in imaging and protocols since the screening rounds in the NLST were completed," said James Mulshine, MD, LCA Board member and Associate Provost for Research at Rush University.

"This is critical. 160,000 people a year are dying of lung cancer and that is close to a third of all cancer deaths in the United States," he said.

Over the past two years, in addition to LCA, the National Comprehensive Cancer Network (NCCN), American Association of Thoracic Surgeons (AATS), and others have publicly supported screening those at risk.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs